A study published April 6, 2026, in JAMA Internal Medicine found that people seeking medication abortion often reached the same eligibility conclusions as clinicians when using prototype “over-the-counter-style” packaging and a drug facts label. Researchers and outside experts said the results add to evidence that self-screening could work, though any move to over-the-counter sales would face major regulatory and political hurdles.
Dr. Daniel Grossman, an obstetrician-gynecologist at the University of California, San Francisco and director of Advancing New Standards in Reproductive Health (ANSIRH), was involved in research examining whether patients can determine their own eligibility for medication abortion using prototype labeling.
In the study, participants seeking medication abortion used prototype packaging designed to resemble an over-the-counter product—referred to in coverage as “MiMi,” containing mifepristone and misoprostol—and then assessed whether they met eligibility criteria. Clinicians independently evaluated eligibility for comparison.
The paper reported high agreement between participants’ self-assessments and clinicians’ evaluations, a result the researchers said supports the feasibility of self-screening with clear labeling. The authors also noted limitations, including the study’s sample size, meaning the findings should be interpreted cautiously and tested further in broader settings.
In an accompanying commentary published in the same issue, Dr. Sonya Borrero of the University of Pittsburgh argued that the study adds to the growing evidence base for over-the-counter-style access to medication abortion, while noting that FDA decisions do not occur in a political vacuum—particularly after the Supreme Court’s 2022 decision in Dobbs v. Jackson Women’s Health Organization.
Experts cited in coverage also compared the self-screening approach to how medication abortion is already provided in some telemedicine models, where eligibility is often determined through patient-reported information paired with clinical review.
Even with research exploring a potential pathway to nonprescription access, there is currently no publicly identified, active FDA application to switch the mifepristone-misoprostol regimen to over-the-counter status.
The broader policy environment remains contentious. Several states have enacted near-total abortion bans, while others have pursued additional restrictions on medication abortion. At the federal level, Sen. Josh Hawley, a Missouri Republican, introduced legislation in March 2026 that would withdraw FDA approval of mifepristone for abortion. Separately, Sen. Bill Cassidy, the Louisiana Republican who chairs the Senate Health, Education, Labor and Pensions (HELP) Committee, announced in March 2026 that the committee had opened an investigation into abortion-drug manufacturers and urged the FDA to crack down on illegal online sellers.
Louisiana has also taken state-level action: in May 2024, Gov. Jeff Landry signed a measure classifying mifepristone and misoprostol as Schedule IV “controlled dangerous substances” under state law.
Meanwhile, litigation continues to shape access. Anti-abortion state officials have sought court orders aimed at limiting the distribution of mifepristone, including efforts that abortion-rights groups warn could curtail telemedicine provision nationwide.
Against that backdrop, the FDA has faced renewed calls to revisit its mifepristone policies. Grossman and other researchers have said that, regardless of scientific questions about feasibility, the current political climate makes an over-the-counter switch unlikely in the near term.
